Therapeutic Area | MeSH |
---|---|
neoplasms | D009369 |
hemic and lymphatic diseases | D006425 |
immune system diseases | D007154 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
TARGRETIN | Bausch Health Companies | N-021056 RX | 2000-06-28 | 1 products, RLD, RS |
TARGRETIN | Bausch Health Companies | N-021055 RX | 1999-12-29 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
bexarotene | ANDA | 2024-11-27 |
targretin | New Drug Application | 2020-04-30 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
t-cell lymphoma cutaneous | — | D016410 | C84.A |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Lymphoma | D008223 | — | C85.9 | — | — | — | 1 | — | 1 |
T-cell lymphoma | D016399 | — | — | — | — | — | 1 | — | 1 |
T-cell lymphoma peripheral | D016411 | — | — | — | — | — | 1 | — | 1 |
T-cell lymphoma cutaneous | D016410 | — | C84.A | — | — | — | 1 | — | 1 |
Drug common name | Bexarotene |
INN | bexarotene |
Description | Bexarotene is a retinoid, a member of benzoic acids and a member of naphthalenes. It has a role as an antineoplastic agent. |
Classification | Small molecule |
Drug class | arotinoid derivatives |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | C=C(c1ccc(C(=O)O)cc1)c1cc2c(cc1C)C(C)(C)CCC2(C)C |
PDB | — |
CAS-ID | 153559-49-0 |
RxCUI | — |
ChEMBL ID | CHEMBL1023 |
ChEBI ID | 50859 |
PubChem CID | 82146 |
DrugBank | DB00307 |
UNII ID | A61RXM4375 (ChemIDplus, GSRS) |